Key result
AT2R agonists promote natriuresis and reduce vascular and renal injury without acutely lowering blood pressure.
Why the study?
Does AT2-receptor stimulation with novel agonists improve vascular biology, kidney function, and blood pressure in preclinical models of hypertension and end-organ damage?
Does AT2-receptor stimulation with novel agonists improve vascular biology, kidney function, and blood pressure in preclinical models of hypertension and end-organ damage?
Answers are grounded in this paper and cite their sources.
Preclinical evidence indicates that while AT2R agonists like Compound 21 are unsuitable for antihypertensive monotherapy due to a lack of acute blood pressure lowering, they offer significant vascular and renal protective effects that could be beneficial when combined with established antihypertensives.
The angiotensin type 2 receptor (AT2R) and the receptor MAS are receptors within the renin-angiotensin system, which mediate tissue-protective actions such as anti-inflammation, antifibrosis, and antiapoptosis. In recent years, several programs have been launched in order to develop drugs that act as agonists on the AT2R or MAS to take therapeutic advantage of the protective and regenerative properties of these receptors. This review article will focus on recent data obtained in preclinical animal and in vitro models with new AT2R-agonistic molecules (Compound 21 and β-amino acid substituted angiotensin II) and with relevance for blood pressure (BP) regulation or hypertensive end-organ damage. These data will include studies on vasodilation/vasoconstriction in isolated resistance arteries ex vivo, studies on kidney function, studies on vascular remodeling, and studies that measured the net effect of AT2R stimulation on BP in vivo. Current data indicate that although AT2R stimulation causes vasodilation ex vivo and promotes natriuresis, it does not alter BP levels in vivo acutely - at least as long as there is no additional low-dose blockade of AT1R. However, AT2R stimulation alone is able to attenuate hypertension-induced vascular remodeling and reduce arterial stiffening, which in more chronic settings and together with the natriuretic effect may result in modest lowering of BP. We conclude from these preclinical data that AT2R agonists are not suitable for antihypertensive monotherapy, but that this new future drug class may be beneficial in combination with established antihypertensives for the treatment of hypertension with improved protection from end-organ damage.
No takes yet. Share an insight, caveat, or question.
Steckelings et al. (2013) conducted a review in Hypertension and hypertensive end-organ damage. Angiotensin type 2 receptor (AT2R) agonists (Compound 21, LP2-3, and beta-amino acid substituted angiotensin II) vs. Vehicle, angiotensin type 1 receptor (AT1R) blockers (ARBs), or AT2R antagonist (PD 123319) was evaluated on Blood pressure regulation, vascular biology (vasodilation and vascular remodeling), and kidney function (natriuresis and renal inflammation/injury). AT2R agonists induce ex vivo vasodilation, promote natriuresis, and attenuate vascular remodeling and renal inflammation in preclinical models without acutely lowering blood pressure in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: